Liberal MP Christian Porter has asked a court to ensure Nine and News Corp. do not use secret portions of ABC’s defence to his defamation allegations, which the media giants accessed as intervenors in the former federal Attorney-General’s case.
A plastic surgeon who was subjected to an “online tirade of criticism, negative reviews and abuse” by a former patient has won $450,000 in defamation damages.
The right approach to determining patentability of a computer-implemented invention is to first assess whether it is more than a mere scheme or business method, the Full Federal Court has been told in an appeal of a ruling backing IP Australia’s revocation of two patents by plumbing company Repipe.
Mining company TerraCom has asked a court to rule on the privilege status of a report by PriceWaterhouseCoopers, produced in reponse to “serious allegations” by a former employee over the falsification of coal quality results.
The consumer regulator has launched court proceedings against luxury car maker Mercedes-Benz for allegedly exposing consumers to serious injury or death by failing to comply with obligations under a compulsory recall of potentially deadly Takata airbags.
Financial services giant Willis Towers Watson ordered a former executive to lie to clients on his way out of the organisation and imposed an “unreasonable” two-year employment restraint, a NSW Supreme Court has found.
Crown Resorts chair Helen Coonan and the CEO of Crown Melbourne will step down at the end of this month, the latest heads to roll as the casino operator attempts to persuade Royal Commissioner Ray Finkelstein QC that it should keep its Victorian licence.
National Australia Bank has admitted in court it broke the law by charging fees it was not entitled to collect, but the bank and the corporate regulator are $25 million apart on what is an appropriate penalty.
Regional Express has engaged Big Six firm Clayton Utz to investigate potential court action against rival airline Qantas for alleged anticompetitive conduct.
Generic drug maker Mayne Pharma Group has been hit with a shareholder class action over disclosures in relation to price-fixing allegations by US authorities.